Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a human Fc enhanced next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, which is being developed by CTEP as an anticancer agent in collaboration with Agenus Inc. CTEP will also consider requests to supply botensilimab for nonclinical studies. All clinical and nonclinical researchers interested in working with the agent are welcome to apply. All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.
今天，艾吉納斯公司（"艾吉納斯"）（納斯達克：AGEN）是開發新型免疫治療癌症代理方面的領導者。該公司今天宣佈，癌症治療評估計劃（CTEP）正在接受意向書（LOIs）以使用botensilimab（BOT）進行臨床研究，BOT是一種人Fc增強的下一代抗胞毒性T淋巴細胞相關蛋白4（CTLA-4）抗體。CTEP正在與Agenus Inc.合作，將BOT作爲抗癌藥物開發。CTEP還將考慮提供botensilimab用於非臨床研究。所有對與該藥物合作感興趣的臨床和非臨床研究人員都可以申請。CTEP批准的所有建議都將發送給行業合作伙伴，以確認提供研究所需藥物。
譯文內容由第三人軟體翻譯。